Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2005 5
2006 4
2007 2
2008 5
2009 16
2010 7
2011 9
2012 8
2013 5
2014 11
2015 8
2016 15
2017 15
2018 10
2019 21
2020 13
2021 7
2022 16
2023 3
Text availability
Article attribute
Article type
Publication date

Search Results

160 results
Results by year
Filters applied: . Clear all
Page 1
Dexlansoprazole.
[No authors listed] [No authors listed] 2022 May 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2022 May 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000653 Free Books & Documents. Review.
Dexlansoprazole is the R-enantiomer of the proton-pump inhibitor, lansoprazole. No information is available on the use of dexlansoprazole or lansoprazole during breastfeeding. However, lansoprazole has been used safely in newborn infants, so it is unlikely that the
Dexlansoprazole is the R-enantiomer of the proton-pump inhibitor, lansoprazole. No information is available on the use of dexlanso
Dexlansoprazole MR.
Aslam N, Wright R. Aslam N, et al. Expert Opin Pharmacother. 2009 Oct;10(14):2329-36. doi: 10.1517/14656560903198978. Expert Opin Pharmacother. 2009. PMID: 19708852 Review.
OBJECTIVE: The purpose of this paper is to discuss the pharmacology of dexlansoprazole DDR and to provide a concise review of all available studies showing its efficacy. ...METHODS: This manuscript is based on a review of all currently available medical literature on de
OBJECTIVE: The purpose of this paper is to discuss the pharmacology of dexlansoprazole DDR and to provide a concise review of all ava …
A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Frelinger AL 3rd, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, Michelson AD. Frelinger AL 3rd, et al. J Am Coll Cardiol. 2012 Apr 3;59(14):1304-11. doi: 10.1016/j.jacc.2011.12.024. J Am Coll Cardiol. 2012. PMID: 22464259 Free article. Clinical Trial.
The area under the curve for clopidogrel active metabolite decreased significantly with esomeprazole but not with dexlansoprazole or lansoprazole. Similarly, esomeprazole but not dexlansoprazole or lansoprazole significantly reduced the effect of clopidogrel on vaso …
The area under the curve for clopidogrel active metabolite decreased significantly with esomeprazole but not with dexlansoprazole or …
Dexlansoprazole MR: a review.
Hershcovici T, Jha LK, Fass R. Hershcovici T, et al. Ann Med. 2011 Aug;43(5):366-74. doi: 10.3109/07853890.2011.554429. Epub 2011 Mar 3. Ann Med. 2011. PMID: 21366513 Review.
Dexlansoprazole MR is the R-enantiomer of lansoprazole that is delivered by a novel system, the dual delayed release formulation. ...Dexlansoprazole could be taken without regard to food. Overall, dexlansoprazole is well tolerated and has a comparable side-ef
Dexlansoprazole MR is the R-enantiomer of lansoprazole that is delivered by a novel system, the dual delayed release formulation. ...
Addendum: Dexlansoprazole for GERD.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2022 May 16;64(1650):79-80. Med Lett Drugs Ther. 2022. PMID: 35536912 No abstract available.
Dexlansoprazole prevents pulmonary artery hypertension by inhibiting pulmonary artery smooth muscle cell to fibroblast transition.
Jiao Q, Zou F, Li S, Wang J, Xiao Y, Guan Z, Dong L, Tian J, Li S, Wang R, Zhang J, Li H. Jiao Q, et al. Am J Transl Res. 2022 Aug 15;14(8):5466-5479. eCollection 2022. Am J Transl Res. 2022. PMID: 36105026 Free PMC article.
OBJECTIVES: To validate that dexlansoprazole, an anti-acid drug, can prevent pulmonary artery hypertension (PAH) in preclinical animal models and find the possible mechanism of action of dexlansoprazole for this new indication. ...Consequently, PAH might be a new in …
OBJECTIVES: To validate that dexlansoprazole, an anti-acid drug, can prevent pulmonary artery hypertension (PAH) in preclinical anima …
Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
Abel C, Desilets AR, Willett K. Abel C, et al. Ann Pharmacother. 2010 May;44(5):871-7. doi: 10.1345/aph.1M685. Epub 2010 Apr 6. Ann Pharmacother. 2010. PMID: 20371754 Review.
CONCLUSIONS: Dexlansoprazole provides another treatment option for the management of EE and symptoms of heartburn. Considering that the cost of dexlansoprazole is not favorable, further studies evaluating potential advantages over other agents are necessary to defin …
CONCLUSIONS: Dexlansoprazole provides another treatment option for the management of EE and symptoms of heartburn. Considering that t …
Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
Emerson CR, Marzella N. Emerson CR, et al. Clin Ther. 2010 Aug;32(9):1578-96. doi: 10.1016/j.clinthera.2010.08.008. Clin Ther. 2010. PMID: 20974316 Review.
BACKGROUND: Dexlansoprazole, the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties. ...Dexlansoprazole was well tolerated compared with placebo or lansoprazole in all studies. ...
BACKGROUND: Dexlansoprazole, the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual …
Dexlansoprazole - a new-generation proton pump inhibitor.
Skrzydło-Radomańska B, Radwan P. Skrzydło-Radomańska B, et al. Prz Gastroenterol. 2015;10(4):191-6. doi: 10.5114/pg.2015.56109. Epub 2015 Dec 16. Prz Gastroenterol. 2015. PMID: 26759624 Free PMC article. Review.
Dexlansoprazole modified release (MR) is an R-enantiomer of lansoprazole and a new-generation proton pump inhibitor exhibiting high efficacy in the treatment of symptoms and lesions associated with erosive oesophagitis caused by gastroesophageal reflux disease (GERD). ...T
Dexlansoprazole modified release (MR) is an R-enantiomer of lansoprazole and a new-generation proton pump inhibitor exhibiting high e
Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.
Croxtall JD, Scott LJ. Croxtall JD, et al. Drugs. 2010 Aug 20;70(12):1593-601. doi: 10.2165/11295960-000000000-00000. Drugs. 2010. PMID: 20687622 Review.
Dexlansoprazole modified release (dexlansoprazole MR) is an orally administered delayed-release formulation of the R-enantiomer of the proton pump inhibitor lansoprazole that is effective in improving the healing of all grades of erosive oesophagitis, maintaining th
Dexlansoprazole modified release (dexlansoprazole MR) is an orally administered delayed-release formulation of the R-enantiome
160 results